Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors

Bone metastases are common complications of solid tumors. The outcome is poor despite major progress in cancer therapies. We describe a multicenter, open-label, phase 1, dose escalation and expansion trial of JMT103, a novel fully humanized receptor activator of nuclear factor kappa-B ligand (RANKL)...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xu, Xue, Junli, Ge, Xiaoxiao, Li, Jin, Li, Huiping, Xue, Liqiong, Di, Lijun, Tang, Wenbo, Song, Guohong, Li, Qun, Jiang, Hanfang, Zhao, Wei, Lin, Fengjuan, Shao, Bin, Yang, Xiugao, Wu, Zhufeng, Zhang, Tianyi, Wang, Chenchen, Guo, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389458/
https://www.ncbi.nlm.nih.gov/pubmed/35992822
http://dx.doi.org/10.3389/fonc.2022.971594

Ejemplares similares

Ejemplares similares